We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Novozymes Biopharma to Present Latest Research on Recombinant Human Albumin at AAPS
News

Novozymes Biopharma to Present Latest Research on Recombinant Human Albumin at AAPS

Novozymes Biopharma to Present Latest Research on Recombinant Human Albumin at AAPS
News

Novozymes Biopharma to Present Latest Research on Recombinant Human Albumin at AAPS

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Novozymes Biopharma to Present Latest Research on Recombinant Human Albumin at AAPS"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Novozymes Biopharma, part of Novozymes A/S announces a new scientific poster on recombinant human albumin to be presented at the 2011 AAPS National Biotechnology Conference, May 16-18, San Francisco, California.

The poster reveals the results of the company's latest study on the use of recombinant human albumin for the stabilization of therapeutic proteins. For more information or to request a copy of the scientific poster, please visit table #32 at the 2011 AAPS National Biotechnology Conference or www.biopharma.novozymes.com

The therapeutic and ultimately the commercial success of a protein-based drug depends upon the ability to produce a formulation with an adequate stability profile. The mechanisms of protein instability are complex and typically multiple excipients are required to address factors such as aggregation, oxidation and nonspecific adsorption during protein formulation.

"We are proud to present our latest, breakthrough research on recombinant human albumin and share our invaluable knowledge with other industry  experts", comments Dermot Pearson, marketing director at Novozymes Biopharma. "As a leader in biomanufacturing and process development, we continue to perform studies designed to demonstrate how animal-free rAlbumin can help the industry optimize drug formulation, development and delivery."

The new poster, entitled "Recombinant Human Albumin: A Multifunctional Excipient for the Stabilisation of Therapeutic Protein Formulations", demonstrates the potential for recombinant human albumin (rAlbumin) to act as a multifunctional stabilisation excipient for protein and peptide formulations. The poster describes the study undertaken to investigate the stability of the rAlbumin with respect to pH and temperature to assess the suitability of this molecule for incorporation into protein formulations.

The study results indicate that rAlbumin is a multifunctional excipient, protecting protein-based active ingredients against aggregation, oxidation and non-specific binding in solution. The multifunctional nature of rAlbumin may lead to opportunities to explore simpler protein formulations with reduced numbers of excipients. Additionally, the stability of the molecule reveals its potential to be used under a wide range of formulation conditions.

For further information on Novozymes products or to request a copy of the new scientific poster, please visit table #32 at the 2011 AAPS National Biotechnology Conference.

Advertisement